Advertisement

Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosis

Open AccessPublished:October 26, 2022DOI:https://doi.org/10.1016/j.jhep.2022.10.008

      Highlights

      • A non-hepatotropic viral signature was identified in individuals with AD of cirrhosis.
      • This viral signature correlated with clinical outcomes.
      • CMV reactivation might play a pathogenic role in AD and progression toward ACLF.
      • Further refinement and validation are needed to define the clinical relevance of our results.

      Background & Aims

      Although the effect of bacterial infection on cirrhosis has been well-described, the effect of non-hepatotropic virus (NHV) infection is unknown. This study evaluated the genome fragments of circulating microorganisms using metagenomic next-generation sequencing (mNGS) in individuals with acute decompensation (AD) of cirrhosis, focusing on NHVs, and related the findings to clinical outcomes.

      Methods

      Plasma mNGS was performed in 129 individuals with AD of cirrhosis in the study cohort. Ten healthy volunteers and 20, 39, and 81 individuals with stable cirrhosis, severe sepsis and hematological malignancies, respectively, were enrolled as controls. Validation assays for human cytomegalovirus (CMV) reactivation were performed in a validation cohort (n = 58) and exploratory treatment was instituted.

      Results

      In the study cohort, 188 microorganisms were detected in 74.4% (96/129) of patients, including viruses (58.0%), bacteria (34.1%), fungi (7.4%) and chlamydia (0.5%). A NHV signature was identified in individuals with AD, and CMV was the most frequent NHV, which correlated with the clinical effect of empirical antibiotic treatment, progression to acute-on-chronic liver failure, and 90-day mortality. The NHV signature in individuals with acute-on-chronic liver failure was similar to that in those with sepsis and hematological malignancies. CMV was detected in 24.1% (14/58) of patients in the validation cohort. Of the 14 cases with detectable CMV by mNGS, nine were further validated by real-time PCR or pp65 antigenemia testing. Three patients with CMV reactivation received ganciclovir therapy in an exploratory manner and experienced clinical resolutions.

      Conclusions

      The results of this study suggest that NHVs may play a pathogenic role in complicating the course of AD. Further validation is needed to define whether this should be incorporated into the routine management of individuals with AD of cirrhosis.

      Impact and implications

      A non-hepatotropic virus (NHV) signature, which was similar to that in individuals with sepsis and hematological malignancies, was identified in individuals with acute decompensation of cirrhosis. The detected viral signature had clinical correlates, including clinical efficacy of empirical antibiotic treatment, progression to acute-on-chronic liver failure and short-term mortality. Cytomegalovirus reactivation, which is treatable, may adversely affect clinical outcomes in some individuals with decompensated cirrhosis. Routine screening for NHVs, especially cytomegalovirus, may be useful for the management of individuals with acute decompensation of cirrhosis.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Albillos A.
        • Martin-Mateos R.
        • van der Merwe S.
        • Wiest R.
        • Jalan R.
        • Álvarez-Mon M.
        Cirrhosis-associated immune dysfunction.
        Nat Rev Gastro Hepat. 2022; 19: 112-134
        • Arroyo V.
        • Moreau R.
        • Jalan R.
        Acute-on-Chronic liver failure.
        N Engl J Med. 2020; 382: 2137-2145
        • Bajaj J.S.
        • Kamath P.S.
        • Reddy K.R.
        The evolving challenge of infections in cirrhosis.
        N Engl J Med. 2021; 384: 2317-2330
        • Trebicka J.
        • Fernandez J.
        • Papp M.
        • Caraceni P.
        • Laleman W.
        • Gambino C.
        • et al.
        PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
        J Hepatol. 2021; 74: 1097-1108
        • Bonnel A.R.
        • Bunchorntavakul C.
        • Reddy K.R.
        Immune dysfunction and infections in patients with cirrhosis.
        Clin Gastroenterol Hepatol. 2011; 9: 727-738
        • Wu T.
        • Li J.
        • Shao L.
        • Xin J.
        • Jiang L.
        • Zhou Q.
        • et al.
        Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
        Gut. 2018; 67: 2181-2191
        • Radha K.Y.
        • Saraswat V.A.
        • Das K.
        • Himanshu G.
        • Yachha S.K.
        • Aggarwal R.
        • et al.
        Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis.
        Liver Int. 2009; 29: 392-398
        • Somasekar S.
        • Lee D.
        • Rule J.
        • Naccache S.N.
        • Stone M.
        • Busch M.P.
        • et al.
        Viral surveillance in serum samples from patients with acute liver failure by metagenomic next-generation sequencing.
        Clin Infect Dis. 2017; 65: 1477-1485
        • Mellinger J.L.
        • Rossaro L.
        • Naugler W.E.
        • Nadig S.N.
        • Appelman H.
        • Lee W.M.
        • et al.
        Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group.
        Dig Dis Sci. 2014; 59: 1630-1637
        • Forbes J.D.
        • Knox N.C.
        • Ronholm J.
        • Pagotto F.
        • Reimer A.
        Metagenomics: the next culture-independent game changer.
        Front Microbiol. 2017; 8: 1069
        • Gu W.
        • Deng X.
        • Lee M.
        • Sucu Y.D.
        • Arevalo S.
        • Stryke D.
        • et al.
        Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids.
        Nat Med. 2021; 27: 115-124
        • Blauwkamp T.A.
        • Thair S.
        • Rosen M.J.
        • Blair L.
        • Lindner M.S.
        • Vilfan I.D.
        • et al.
        Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease.
        Nat Microbiol. 2019; 4: 663-674
        • Wilson M.R.
        • Sample H.A.
        • Zorn K.C.
        • Arevalo S.
        • Yu G.
        • Neuhaus J.
        • et al.
        Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis.
        N Engl J Med. 2019; 380: 2327-2340
        • Li B.
        • He Q.
        • Rui Y.
        • Chen Y.
        • Jalan R.
        • Chen J.
        Rapid detection for infected ascites in cirrhosis using metagenome next-generation sequencing: a case series.
        Liver Int. 2022; 42: 173-179
        • Li B.
        • Yang C.
        • Qian Z.
        • Huang Y.
        • Wang X.
        • Zhong G.
        • et al.
        Spontaneous fungal ascites infection in patients with cirrhosis: an analysis of 10 cases.
        Infect Dis Ther. 2021; 10: 1033-1043
        • Ljungman P.
        • Boeckh M.
        • Hirsch H.H.
        • Josephson F.
        • Lundgren J.
        • Nichols G.
        • et al.
        Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.
        Clin Infect Dis. 2017; 64: 87-91
        • De Broucker C.
        • Plessier A.
        • Ollivier-Hourmand I.
        • Dharancy S.
        • Bureau C.
        • Cervoni J.
        • et al.
        Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease.
        J Hepatol. 2022; 76: 115-122
        • Weiss E.
        • Rautou P.E.
        • Fasseu M.
        • Giabicani M.
        • de Chambrun M.
        • Wan J.
        • et al.
        Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
        J Hepatol. 2017; 66: 930-941
        • Vine L.J.
        • Shepherd K.
        • Hunter J.G.
        • Madden R.
        • Thornton C.
        • Ellis V.
        • et al.
        Characteristics of Epstein-Barr virus hepatitis among patients with jaundice or acute hepatitis.
        Aliment Pharmacol Ther. 2012; 36: 16-21
        • Levitsky J.
        • Duddempudi A.T.
        • Lakeman F.D.
        • Whitley R.J.
        • Luby J.P.
        • Lee W.M.
        • et al.
        Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure.
        Liver Transpl. 2008; 14: 1498-1504
        • Singh N.
        • Winston D.J.
        • Razonable R.R.
        • Lyon G.M.
        • Silveira F.P.
        • Wagener M.M.
        • et al.
        Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial.
        JAMA. 2020; 323: 1378-1387
        • Trebicka J.
        • Macnaughtan J.
        • Schnabl B.
        • Shawcross D.L.
        • Bajaj J.S.
        The microbiota in cirrhosis and its role in hepatic decompensation.
        J Hepatol. 2021; 75: S67-S81
        • Mansfield S.
        • Griessl M.
        • Gutknecht M.
        • Cook C.H.
        Sepsis and cytomegalovirus: foes or conspirators?.
        Med Microbiol Immunol. 2015; 204: 431-437
        • Piano S.
        • Singh V.
        • Caraceni P.
        • Maiwall R.
        • Alessandria C.
        • Fernandez J.
        • et al.
        Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide.
        Gastroenterology. 2019; 156: 1368-1380
        • Schierwagen R.
        • Alvarez-Silva C.
        • Madsen M.
        • Kolbe C.C.
        • Meyer C.
        • Thomas D.
        • et al.
        Circulating microbiome in blood of different circulatory compartments.
        Gut. 2019; 68: 578-580